Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil.

B N Becker1

  • 1Department of Medicine, University of Wisconsin Medical School, Madison, USA. bnb@medicine.wisc.edu

Transplantation Proceedings
|December 1, 1999
PubMed
Summary
This summary is machine-generated.

Mycophenolate mofetil (MMF) is an effective immunosuppressant for preventing acute rejection (AR) in various organ transplant types. This medication is now a standard part of post-transplant care.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kidney and pancreas transplantation in the United States, 1999-2008: the changing face of living donation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2010
Same author

Blood pressure control in kidney transplantation: therapeutic implications.

Journal of human hypertension·2004
Same author

Sirolimus monotherapy following Campath-1H induction.

Transplantation proceedings·2003
Same author

Simultaneous pancreas-kidney and pancreas transplantation.

Minerva urologica e nefrologica = The Italian journal of urology and nephrology·2003
Same author

Type 2 angiotensin II receptor expression in human renal allografts: an association with chronic allograft nephropathy.

Clinical nephrology·2002
Same author

Donor-derived small cell lung carcinoma in a kidney transplant recipient.

Cancer·2001
Same journal

Analysis of the Cost of Maintaining Effective Donors and Nondonors of Organs and Tissues in Intensive Care Units.

Transplantation proceedings·2026
Same journal

Adolescence and Pediatric Heart Transplantation: Impact of Non-Adherence on Mortality: A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Impact of Family-Based Care on the Outcome of Brain Death and Humanization in the Process of Multiple Organ Donation: Case Report.

Transplantation proceedings·2026
Same journal

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
Same journal

Evaluating CMV Risk Stratification, Donor Characteristics, and Post-Transplant Outcomes in Kidney Transplant Recipients: A Retrospective Eurotransplant Center Analysis.

Transplantation proceedings·2026
Same journal

Twenty-One Years of Insights From A Single-Center Living Kidney Donation Program.

Transplantation proceedings·2026
See all related articles

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • Acute rejection (AR) remains a significant challenge in organ transplantation.
  • Effective immunosuppression is crucial for graft survival.
  • Mycophenolate mofetil (MMF) has emerged as a key therapeutic agent.

Purpose of the Study:

  • To evaluate the efficacy of MMF in preventing AR across different transplant types.
  • To establish MMF's role in the current immunosuppressive strategy.

Main Methods:

  • Review of clinical studies and transplant outcomes.
  • Analysis of MMF's impact on AR rates in diverse patient populations.

Main Results:

  • MMF demonstrates proven efficacy in preventing AR.
  • Successful application observed in various transplantation scenarios.

    • Conclusions:

    • MMF is a valuable component of the immunosuppressive regimen.
    • Its use is well-established for preventing AR in transplantation.